X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HS-001 consists allogeneic iPSC-derived, highly purified ventricular cardiomyocyte spheroids. It improves the retention rate and viability of the cell transplant compared to single cell suspensions. It is being developed for restore heart function in advanced heart failure.
Lead Product(s): HS-001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HS-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2023
Details:
HS-001 is an investigational cell therapy consisting of clusters of purified heart muscle cells (cardiomyocyte spheroids) derived from induced pluripotent stem cells (iPSCs) that are designed to restore heart muscle and function in patients with advanced heart failure.
Lead Product(s): HS-001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HS-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2023
Details:
Heartseed plans to use the new funds to accelerate the initiation of global clinical trial of our lead asset, HS-001 for HF as well as to confirm its proof of concept in Phase 1/2 LAPiS study in Japan.
Lead Product(s): Allogeneic iPSC-derived Cardiomyocytes
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HS-001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: UTokyo Innovation Platform
Deal Size: $37.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing June 11, 2021
Details:
HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells. Heartseed is planning to initiate a phase 1/2 clinical trial in Japan in the second half of 2021.
Lead Product(s): Allogeneic iPSC-derived Cardiomyocytes
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HS-001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $598.0 million Upfront Cash: $55.0 million
Deal Type: Collaboration June 01, 2021
Details:
Through this partnership, Heartseed will leverage ICF’s global network of academia and research institutions to explore iPS-Cell and Cardiomyocyte-related business opportunities.
Lead Product(s): Allogeneic iPSC-derived cardiomyocytes
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Itochu Chemical Frontier
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
